Nitric oxide: Target for therapeutic strategies in alzheimer's disease

Current Pharmaceutical Design

Volumn 16, Issue 25, 2010, Pages 2837-2850

  Fernandez, A P ^a   Pozo Rodrigalvarez, A ^a   Serrano, J ^a   Martinez Murillo, R ^a  

^a INSTITUTO CAJAL   (Spain)

Author keywords

Acetylcholinesterase; Alzheime s disease; Amyloid beta peptide; Immunotherapy; Neurodegeneration; Neuroinflammation; Nitric oxide; Nitric oxide synthase inhibitors

Indexed keywords

AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; BIS 7 COGNITIN; CATALPOL; CHOLINESTERASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DIMEBON; DONEPEZIL; DP 55; ENZYME INHIBITOR; FLURBIPROFEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; GALANTAMINE; GEMFIBROZIL; GT 1061; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMANTINE; MUSCARINIC AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NCX 2216; NITRIC ACID DERIVATIVE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; RESVERATROL; RETINOIC ACID; RIVASTIGMINE; TACRINE; THIOCTIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAS 203;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN CELL; CELL DAMAGE; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE CONTROL; DISEASE COURSE; DRUG DESIGN; DRUG EFFICACY; DRUG METABOLISM; DRUG TARGETING; EXCITOTOXICITY; GENETIC RISK; HUMAN; IMMUNOTHERAPY; NEUROPROTECTION; NITRERGIC NERVE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; SYMPTOM; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 77957964186     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793176590     Document Type: Article

References (219)

1. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. AnEnglish translation of Alzheimer's 1907 paper, Uber eine eigenar-tige Erkankung der Hirnrinde. Clin Anat 1995; 8(6): 429-31.
2. Morris JC, Ernesto C, Schafer K, et al. Clinical dementia ratingtraining and reliability in multicenter studies: the Alzheimer's Dis-ease Cooperative Study experience. Neurology 1997; 48(6): 1508-10.
3. Selkoe DJ. Cell biology of the amyloid beta-protein precursor andthe mechanism of Alzheimer's disease. Annu Rev Cell Biol 1994;10: 373-403.
4. Henderson.S. Epidemiology of dementia. Ann Med Interne (Paris)1998; 149(4): 181-6.
5. Cacabelos R. Influence of pharmacogenetic factors on Alzheimer'sdisease therapeutics. Neurodegener Dis 2008; 5(3-4): 176-8.
6. Zawia NH, Lahiri DK, Cardozo-Pelaez F. Epigenetics, oxidativestress, and Alzheimer disease. Free Radic Biol Med 2009; 46(9):1241-9.
7. Kang J, Lemaire HG, Unterbeck A, et al. The precursor of Alz-heimer's disease amyloid A4 protein resembles a cell-surface recep-tor. Nature 1987; 325(6106): 733-6.
8. Naslund J, Schierhorn A, Hellman U, et al. Relative abundance ofAlzheimer A beta amyloid peptide variants in Alzheimer diseaseand normal aging. Proc Natl Acad Sci USA 1994; 91(18): 8378-82.
9. Sun X, Chiu CC, Liebson E, et al. Depression and plasma amyloidbeta peptides in the elderly with and without the apolipoprotein E4allele. Alzheimer Dis Assoc Disord 2009; 23(3): 238-44.
10. Tanzi RE, Bertram L. Twenty years of the Alzheimer's diseaseamyloid hypothesis: a genetic perspective. Cell 2005; 120(4): 545-55.
11. Lukiw WJ. Emerging amyloid beta (Ab) peptide modulators for thetreatment of Alzheimer's disease (AD). Expert Opin Emerg Drugs2008; 13(2): 255-71.
12. Fernandez-Vizarra P, Fernandez AP, Castro-Blanco S, et al. Ex-pression of nitric oxide system in clinically evaluated cases of Alz-heimer's disease. Neurobiol Dis 2004; 15(2): 287-305.
13. Hoozemans JJ, Rozemuller JM, van Haastert ES, Veerhuis R,Eikelenboom P. Cyclooxygenase-1 and -2 in the different stages ofAlzheimer's disease pathology. Curr Pharm Des 2008; 14(14):1419-27.
14. Pasinetti GM. From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs andcyclooxygenase in beta-amyloidosis and clinical dementia. J Alz-heimers Dis 2002; 4(5): 435-45.
15. Velez-Pardo C, Arellano JI, Cardona-Gomez P, Jimenez Del RM, Lopera F, De FJ. CA1 hippocampal neuronal loss in familial Alz-heimer's disease presenilin-1 E280A mutation is related to epilepsy.Epilepsia 2004; 45(7): 751-6.
16. Hu J, Akama KT, Krafft GA, Chromy BA, Van Eldik LJ. Amyloid-beta peptide activates cultured astrocytes: morphological altera-tions, cytokine induction and nitric oxide release. Brain Res 1998;785(2): 195-206.
17. Luth HJ, Holzer M, Gartner U, Staufenbiel M, Arendt T. Expres-sion of endothelial and inducible NOS-isoforms is increased inAlzheimer's disease, in APP23 transgenic mice and after experi-mental brain lesion in rat: evidence for an induction by amyloid pa-thology. Brain Res 2001; 913(1): 57-67.
18. Muller T, Meyer HE, Egensperger R, Marcus K. The amyloidprecursor protein intracellular domain (AICD) as modulator ofgene expression, apoptosis, and cytoskeletal dynamics-Relevancefor Alzheimer's disease. Prog Neurobiol 2008; 85(4): 393-406.
19. Butterfield DA, Perluigi M, Sultana R. Oxidative stress in Alz-heimer's disease brain: new insights from redox proteomics. Eur JPharmacol 2006; 545(1): 39-50.
20. Butterfield DA, Reed TT, Perluigi M, et al. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitiveimpairment: implications for the role of nitration in the progressionof Alzheimer's disease. Brain Res 2007; 1148: 243-8.
21. Sultana R, Perluigi M, Butterfield DA. Protein oxidation and lipidperoxidation in brain of subjects with Alzheimer's disease: insightsinto mechanism of neurodegeneration from redox proteomics. An-tioxid Redox Signal 2006; 8(11-12): 2021-37.
22. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascadehypothesis. Science 1992; 256(5054): 184-5.
23. Gandy S. The role of cerebral amyloid beta accumulation in com-mon forms of Alzheimer disease. J Clin Invest 2005; 115(5): 1121-9.
24. Oddo S, Caccamo A, Cheng D, Laferla FM. Genetically alteringabeta distribution from the brain to the vasculature ameliorates taupathology. Brain Pathol 2008.
25. Bertram L, Tanzi RE. Alzheimer's disease: one disorder, too manygenes? Hum Mol Genet 2004; 13 Spec No 1: R135-41.
26. Nakajima M, Shirasawa T. Presenilin-1-deficient neurons are nitricoxide-dependently killed by hydrogen peroxide in vitro. Neurosci-ence 2004; 125(3): 563-8.
27. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neuro-toxic effects of amyloid beta protein: reversal by tachykinin neu-ropeptides. Science 1990; 250(4978): 279-82.
28. Wolfe MS. Shutting down Alzheimer's. Sci Am 2006; 294(5): 72-9.
29. Perez M, Moran MA, Ferrer I, Avila J, Gomez-Ramos P. Phos-phorylated tau in neuritic plaques of APP(sw)/Tau (vlw) transgenic2846 mice and Alzheimer disease. Acta Neuropathol 2008; 116(4): 409-18.
30. Avila J. Tau kinases and phosphatases. J Cell Mol Med 2008;12(1): 258-9.
31. Hernandez F, Avila J. Tauopathies. Cell Mol Life Sci 2007; 64(17):2219-33.
32. Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplica-tion causes autosomal dominant early-onset Alzheimer disease withcerebral amyloid angiopathy. Nat Genet 2006; 38(1): 24-6.
33. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for thechromosome 1 familial Alzheimer's disease locus. Science 1995;269(5226): 973-7.
34. De SB, Saftig P, Craessaerts K, et al. Deficiency of presenilin-1inhibits the normal cleavage of amyloid precursor protein. Nature1998; 391(6665): 387-90.
35. Duff K, Eckman C, Zehr C, et al. Increased amyloid-beta42(43) inbrains of mice expressing mutant presenilin 1. Nature 1996;383(6602): 710-3.
36. Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alz-heimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996; 17(5): 1005-13.
37. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's dis-ease: progress and problems on the road to therapeutics. Science2002; 297(5580): 353-6.
38. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ.Effects of secreted oligomers of amyloid beta-protein on hippo-campal synaptic plasticity: a potent role for trimers. J Physiol 2006;572(Pt 2): 477-92.
39. Walsh DM, Townsend M, Podlisny MB, et al. Certain inhibitors ofsynthetic amyloid beta-peptide (Abeta) fibrillogenesis block oli-gomerization of natural Abeta and thereby rescue long-term poten-tiation. J Neurosci 2005; 25(10): 2455-62.
40. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimersisolated directly from Alzheimer's brains impair synaptic plasticityand memory. Nat Med 2008; 14(8): 837-42.
41. Tanzi RE. The synaptic Abeta hypothesis of Alzheimer disease.Nat Neurosci 2005; 8(8): 977-9.
42. Knafo S, onso-Nanclares L, Gonzalez-Soriano J, et al. Widespreadchanges in dendritic spines in a model of Alzheimer's disease.Cereb Cortex 2008.
43. Malchiodi-Albedi F, Domenici MR, Paradisi S, Bernardo A, jmone-Cat MA, Minghetti L. Astrocytes contribute to neuronal im-pairment in beta A toxicity increasing apoptosis in rat hippocampalneurons. Glia 2001; 34(1): 68-72.
44. Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDAreceptor trafficking by amyloid-beta. Nat Neurosci 2005; 8(8):1051-8.
45. Deane R, Zlokovic BV. Role of the blood-brain barrier in thepathogenesis of Alzheimer's disease. Curr Alzheimer Res 2007;4(2): 191-7.
46. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M., beta-Amyloid-mediated vasoactivity and vascular endothelial damage.Nature 1996; 380(6570): 168-71.
47. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegenera-tion: lessons from the Alzheimer's amyloid beta-peptide. Nat RevMol Cell Biol 2007; 8(2): 101-12.
48. Rosenberg RN. The molecular and genetic basis of AD: the end ofthe beginning: the 2000 Wartenberg lecture. Neurology 2000;54(11): 2045-54.
49. de la Monte SM, Lu BX, Sohn YK, et al. Aberrant expression ofnitric oxide synthase III in Alzheimer's disease: relevance to cere-bral vasculopathy and neurodegeneration. Neurobiol Aging 2000;21(2): 309-19.
50. Lanni C, Racchi M, Mazzini G, et al. Conformationally alteredp53: a novel Alzheimer's disease marker? Mol Psychiatry 2008;13(6): 641-7.
51. Uberti D, Lanni C, Racchi M, Govoni S, Memo M. Conformation-ally altered p53: a putative peripheral marker for Alzheimer's dis-ease. Neurodegener Dis 2008; 5(3-4): 209-11.
52. Serrano J, Fernandez AP, Martinez-Murillo R, MartInez A. Highsensitivity to carcinogens in the brain of a mouse model of Alz-heimer's disease. Oncogene 2010; 29(15): 2165-71.
53. Su JH, Deng G, Cotman CW. Bax protein expression is increasedin Alzheimer's brain: correlations with DNA damage, Bcl-2 expres-sion, and brain pathology. J Neuropathol Exp Neurol 1997; 56(1):86-93.
54. de la Monte SM, Sohn YK, Wands JR. Correlates of p53- and Fas(CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci11997; 152(1): 73-83.
55. Paradis E, Douillard H, Koutroumanis M, Goodyer C, LeBlanc A.Amyloid beta peptide of Alzheimer's disease downregulates Bcl-2and upregulates bax expression in human neurons. J Neurosci 1996; 16(23): 7533-9.
56. Hooper C, Meimaridou E, Tavassoli M, Melino G, Lovestone S,Killick R. p53 is upregulated in Alzheimer's disease and inducestau phosphorylation in HEK293a cells. Neurosci Lett 2007; 418(1):34-7.
57. Messmer UK, Brune B. Attenuation of p53 expression and Baxdown-regulation during phorbol ester mediated inhibition of apop-tosis. Br J Pharmacol 1997; 121(4): 625-34.
58. Ranjan P, Shrivastava P, Singh SM, Sodhi A, Heintz NH. Bacu-lovirus P35 inhibits NO-induced apoptosis in activated macro-phages by inhibiting cytochrome c release. J Cell Sci 2004; 117(Pt14): 3031-9.
59. Lammich S, Okochi M, Takeda M, et al. Presenilin-dependentintramembrane proteolysis of CD44 leads to the liberation of its in-tracellular domain and the secretion of an Abeta-like peptide. J BiolChem 2002; 277(47): 44754-9.
60. Lathia JD, Mattson MP, Cheng A. Notch: from neural developmentto neurological disorders. J Neurochem 2008; 107(6): 1471-81.
61. Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavageof Alzheimer's amyloid precursor protein by the transmembraneaspartic protease BACE. Science 1999; 286(5440): 735-41.
62. Small SA, Gandy S. Sorting through the cell biology of Alz-heimer's disease: intracellular pathways to pathogenesis. Neuron 2006; 52(1): 15-31.
63. Rajendran L, Honsho M, Zahn TR, et al. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. ProcNatl Acad Sci USA 2006; 103(30): 11172-7.
64. He X, Cooley K, Chung CH, Dashti N, Tang J. Apolipoproteinreceptor 2 and X11 alpha/beta mediate apolipoprotein E-inducedendocytosis of amyloid-beta precursor protein and beta-secretase,leading to amyloid-beta production. J Neurosci 2007; 27(15): 4052-60.
65. Roberson ED, Mucke L. 100 years and counting: prospects fordefeating Alzheimer's disease. Science 2006; 314(5800): 781-4.
66. Haass C, Steiner H. Alzheimer disease gamma-secretase: a com-plex story of GxGD-type presenilin proteases. Trends Cell Biol 2002; 12(12): 556-62.
67. Wolfe MS. When loss is gain: reduced presenilin proteolytic func-tion leads to increased Abeta42/Abeta40. Talking Point on the roleof presenilin mutations in Alzheimer disease. EMBO Rep 2007;8(2): 136-40.
68. Li YM, Xu M, Lai MT, et al. Photoactivated gamma-secretaseinhibitors directed to the active site covalently label presenilin 1.Nature 2000; 405(6787): 689-94.
69. Esler WP, Kimberly WT, Ostaszewski BL, et al. Transition-stateanalogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat Cell Biol 2000; 2(7): 428-34.
70. Xia W, Ray WJ, Ostaszewski BL, et al. Presenilin complexes withthe C-terminal fragments of amyloid precursor protein at the sitesof amyloid beta-protein generation. Proc Natl Acad Sci USA 2000;97(16): 9299-304.
71. Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S.Skeletal and CNS defects in Presenilin-1-deficient mice. Cell 1997;89(4): 629-39.
72. Baki L, Shioi J, Wen P, et al. PS1 activates PI3K thus inhibitingGSK-3 activity and tau overphosphorylation: effects of FAD muta-tions. EMBO J 2004; 23(13): 2586-96.
73. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidy-linositol-3-OH kinase signal transduction. Nature 1995; 376(6541):599-602.
74. Dehvari N, Cedazo-Minguez A, Isacsson O, et al. Presenilin de-pendence of phospholipase C and protein kinase C signaling. JNeurochem 2007; 102(3): 848-57.
75. Rocchi A, Pellegrini S, Siciliano G, Murri L. Causative and suscep-tibility genes for Alzheimer's disease: a review. Brain Res Bull 2003; 61(1): 1-24.
76. Cowburn RF, Popescu BO, Ankarcrona M, Dehvari N, Cedazo-Minguez A. Presenilin-mediated signal transduction. Physiol Behav 2007; 92(1-2): 93-7.
77. Cheung KH, Shineman D, Muller M, et al. Mechanism of Ca2+disruption in Alzheimer's disease by presenilin regulation of InsP3receptor channel gating. Neuron 2008; 58(6): 871-83.
78. Ebinu JO, Yankner BA. A RIP tide in neuronal signal transduction.Neuron 2002; 34(4): 499-502.
79. Marambaud P, Shioi J, Serban G, et al. A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain andregulates disassembly of adherens junctions. EMBO J 2002; 21(8):1948-56.
80. Tandon A, Fraser P. The presenilins. Genome Biol 2002; 3(11):reviews 3014.
81. Dewji NN, Singer SJ. Specific intercellular binding of the beta-amyloid precursor protein to the presenilins induces intercellularsignaling: its significance for Alzheimer's disease. Proc Natl AcadSci USA 1998; 95(25): 15055-60.
82. Laferla FM. Calcium dyshomeostasis and intracellular signalling inAlzheimer's disease. Nat Rev Neurosci 2002; 3(11): 862-72.
83. St George-Hyslop PH. Molecular genetics of Alzheimer's disease.Biol Psychiatry 2000; 47(3): 183-199.
84. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer'sdisease in kindreds with missense mutations in a gene on chromo-some 1 related to the Alzheimer's disease type 3 gene. Nature 1995;376(6543): 775-8.
85. Geling A, Steiner H, Willem M, Bally-Cuif L, Haass C. A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a se-vere neurogenic phenotype in zebrafish. EMBO Rep 2002; 3(7):688-94.
86. Wong GT, Manfra D, Poulet FM, et al. Chronic treatment with thegamma-secretase inhibitor LY-411,575 inhibits beta-amyloid pep-tide production and alters lymphopoiesis and intestinal cell differ-entiation. J Biol Chem 2004; 279(13): 12876-82.
87. Vassar R. Beta-secretase (BACE) as a drug target for Alzheimer'sdisease. Adv Drug Deliv Rev 2002; 54(12): 1589-602.
88. Zhao J, Fu Y, Yasvoina M, et al. Beta-site amyloid precursorprotein cleaving enzyme 1 levels become elevated in neuronsaround amyloid plaques: implications for Alzheimer's diseasepathogenesis. J Neurosci 2007; 27(14): 3639-49.
89. Wang Q, Rowan MJ, Anwyl R. Beta-amyloid-mediated inhibitionof NMDA receptor-dependent long-term potentiation induction in-volves activation of microglia and stimulation of inducible nitricoxide synthase and superoxide. J Neurosci 2004; 24(27): 6049-56.
90. Parameshwaran K, Dhanasekaran M, Suppiramaniam V. Amyloidbeta peptides and glutamatergic synaptic dysregulation. Exp Neurol 2008; 210(1): 7-13.
91. Parameshwaran K, Sims C, Kanju P, et al. Amyloid beta-peptideAbeta(1-42) but not Abeta(1-40) attenuates synaptic AMPA recep-tor function. Synapse 2007; 61(6): 367-74.
92. Gasparini L, Dityatev A. Beta-amyloid and glutamate receptors.Exp Neurol 2008; 212(1): 1-4.
93. Pak T, Cadet P, Mantione KJ, Stefano GB. Morphine via nitricoxide modulates beta-amyloid metabolism: a novel protectivemechanism for Alzheimer's disease. Med Sci Monit 2005; 11(10):BR 357-66.
94. Heneka MT, Wiesinger H, Dumitrescu-Ozimek L, Riederer P,Feinstein DL, Klockgether T. Neuronal and glial coexpression ofargininosuccinate synthetase and inducible nitric oxide synthase inAlzheimer disease. J Neuropathol Exp Neurol 2001; 60(9): 906-16.
95. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergichypothesis of Alzheimer's disease: a review of progress. J NeurolNeurosurg Psychiatry 1999; 66(2): 137-47.
96. Rupsingh R, Borrie M, Smith M, Wells JL, Bartha R. Reducedhippocampal glutamate in Alzheimer disease. Neurobiol Aging 2009.
97. Schaeffer EL, Gattaz WF. Cholinergic and glutamatergic altera-tions beginning at the early stages of Alzheimer disease: participa-tion of the phospholipase A2 enzyme. Psychopharmacology (Berl) 2008; 198(1): 1-27.
98. Nathan C, Calingasan N, Nezezon J, et al. Protection from Alz-heimer's-like disease in the mouse by genetic ablation of induciblenitric oxide synthase. J Exp Med 2005; 202(9): 1163-9.
99. Moncada S. Nitric oxide. J Hypertens Suppl 1994; 12(10): S35-9.
100. Schmidt HH, Walter U. NO at work. Cell 1994; 78(6): 919-25.
101. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology,pathophysiology, and pharmacology. Pharmacol Rev 1991; 43(2):109-42.
102. Law A, Gauthier S, Quirion R. Say NO to Alzheimer's disease: theputative links between nitric oxide and dementia of the Alzheimer'stype. Brain Res Brain Res Rev 2001; 35(1): 73-96.
103. Togo T, Katsuse O, Iseki E. Nitric oxide pathways in Alzheimer'sdisease and other neurodegenerative dementias. Neurol Res 2004;26(5): 563-6.
104. Lipton SA. Failures and successes of NMDA receptor antagonists:molecular basis for the use of open-channel blockers like meman-tine in the treatment of acute and chronic neurologic insults. Neu-roRx 2004; 1(1): 101-10.
105. Hellstrom-Lindahl E. Modulation of beta-amyloid precursor pro-tein processing and tau phosphorylation by acetylcholine receptors.Eur J Pharmacol 2000; 393(1-3): 255-63.
106. Rosengarten B, Paulsen S, Molnar S, Kaschel R, Gallhofer B, KapsM. Acetylcholine esterase inhibitor donepezil improves dynamiccerebrovascular regulation in Alzheimer patients. J Neurol 2006;253(1): 58-64.
107. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholines-terase inhibitors and memantine for treating dementia: evidence re-view for a clinical practice guideline. Ann Intern Med 2008;148(5): 379-97.
108. Galimberti D, Scarpini E. Treatment of Alzheimer's disease: symp-tomatic and disease-modifying approaches. Curr Aging Sci 2010;3(1): 46-56.
109. Fernandez-Bachiller MI, Perez C, Campillo NE, et al. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's dis-ease, with cholinergic, antioxidant, and neuroprotective properties.ChemMedChem 2009; 4(5): 828-41.
110. Chabrier PE, merle-Pallardy C, Auguet M. Nitric oxide synthases:targets for therapeutic strategies in neurological diseases. Cell MolLife Sci 1999; 55(8-9): 1029-35.
111. Law A, Gauthier S, Quirion R. Neuroprotective and neurorescuingeffects of isoform-specific nitric oxide synthase inhibitors, nitricoxide scavenger, and antioxidant against beta-amyloid toxicity. BrJ Pharmacol 2001; 133(7): 1114-24.
112. Xie QW, Cho HJ, Calaycay J, et al. Cloning and characterization ofinducible nitric oxide synthase from mouse macrophages. Science 1992; 256(5054): 225-8.
113. Vodovotz Y, Lucia MS, Flanders KC, et al. Inducible nitric oxidesynthase in tangle-bearing neurons of patients with Alzheimer'sdisease. J Exp Med 1996; 184(4): 1425-33.
114. Chiarini A, Dal P I, Marconi M, Chakravarthy B, Whitfield JF, Armato U. Calcium-sensing receptor (CaSR) in human brain'spathophysiology: roles in late-onset Alzheimer's disease (LOAD). Curr Pharm Biotechnol 2009; 10(3): 317-26.
115. Ali AK, Banks WA, Kumar VB, et al. Nitric oxide activity andisoenzyme expression in the senescence-accelerated mouse p8model of Alzheimer's disease: effects of anti-amyloid antibody andantisense treatments. J Gerontol A Biol Sci Med Sci 2009; 64(10):1025-30.
116. Lee SC, Zhao ML, Hirano A, Dickson DW. Inducible nitric oxidesynthase immunoreactivity in the Alzheimer disease hippocampus:association with Hirano bodies, neurofibrillary tangles, and senileplaques. J Neuropathol Exp Neurol 1999; 58(11): 1163-9.
117. Wong A, Luth HJ, uther-Conrad W, et al. Advanced glycationendproducts co-localize with inducible nitric oxide synthase inAlzheimer's disease. Brain Res 2001; 920(1-2): 32-40.
118. Shibata N, Kobayashi M. [The role for oxidative stress in neurode-generative diseases]. Brain Nerve 2008; 60(2): 157-70.
119. Wang B, Tan S, Yang Z, et al. Association between Alzheimer'sdisease and the NOS3 gene Glu298Asp polymorphism in Chinese. J Mol Neurosci 2008; 34(2): 173-6.
120. Murphy MP, Packer MA, Scarlett JL, Martin SW. Peroxynitrite: abiologically significant oxidant. Gen Pharmacol 1998; 31(2): 179-86.
121. Koppal T, Drake J, Yatin S, et al. Peroxynitrite-induced alterationsin synaptosomal membrane proteins: insight into oxidative stress inAlzheimer's disease. J Neurochem 1999; 72(1): 310-7.
122. Luth HJ, Munch G, Arendt T. Aberrant expression of NOS iso-forms in Alzheimer's disease is structurally related to nitrotyrosineformation. Brain Res 2002; 953(1-2): 135-43.
123. Rodrigo J, Fernandez-Vizarra P, Castro-Blanco S, et al. Nitricoxide in the cerebral cortex of amyloid-precursor protein (SW)Tg2576 transgenic mice. Neuroscience 2004; 128(1): 73-89.
124. Law A, Gauthier S, Quirion R. Say NO to Alzheimer's disease: theputative links between nitric oxide and dementia of the Alzheimer'stype. Brain Res Brain Res Rev 2001; 35(1): 73-96.
125. Flirski M, Sobow T. Biochemical markers and risk factors ofAlzheimer's disease. Curr Alzheimer Res 2005; 2(1): 47-64.
126. Mesenge C, Charriaut-Marlangue C, Verrecchia C, Allix M, BouluRR, Plotkine M. Reduction of tyrosine nitration after N(omega)-nitro-L-arginine-methylester treatment of mice with traumatic braininjury. Eur J Pharmacol 1998; 353(1): 53-7.
127. Murphy GM, Jr., Yang L, Cordell B. Macrophage colony-stimulating factor augments beta-amyloid-induced interleukin-1,interleukin-6, and nitric oxide production by microglial cells. J BiolChem 1998; 273(33): 20967-71.
128. Serrano J, Fernandez AP, Martinez-Murillo R, MartInez A. Highsensitivity to carcinogens in the brain of a mouse model of Alz-heimeŕs disease. Oncogene 2009; In press.
129. Meda L, Cassatella MA, Szendrei GI, et al. Activation of micro-glial cells by beta-amyloid protein and interferon-gamma. Nature 1995; 374(6523): 647-50.
130. Kim YA, Lim SY, Rhee SH, Park KY, Kim CH, Choi BT et al.Resveratrol inhibits inducible nitric oxide synthase and cyclooxy-genase-2 expression in beta-amyloid-treated C6 glioma cells. Int JMol Med 2006; 17(6): 1069-75.
131. Apelt J, Bigl M, Wunderlich P, Schliebs R. Aging-related increasein oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenicTg2576 mice with Alzheimer-like pathology. Int J Dev Neurosci 2004; 22(7): 475-84.
132. Lee J, Chan SL, Mattson MP. Adverse effect of a presenilin-1mutation in microglia results in enhanced nitric oxide and inflam-matory cytokine responses to immune challenge in the brain. Neu-romolecular Med 2002; 2(1): 29-45.
133. de la Monte SM, Wands JR. Molecular indices of oxidative stressand mitochondrial dysfunction occur early and often progress withseverity of Alzheimer's disease. J Alzheimers Dis 2006; 9(2): 167-81.
134. Duncan AJ, Heales SJ. Nitric oxide and neurological disorders. Mol Aspects Med 2005; 26(1-2): 67-96.
135. Medeiros R, Prediger RD, Passos GF, et al. Connecting TNF-alphasignaling pathways to iNOS expression in a mouse model of Alz-heimer's disease: relevance for the behavioral and synaptic deficitsinduced by amyloid beta protein. J Neurosci 2007; 27(20): 5394-404.
136. Stepanichev MY, Onufriev MV, Yakovlev AA, et al. Amyloid-beta(25-35) increases activity of neuronal NO-synthase in rat brain. Neurochem Int 2008; 52(6): 1114-24.
137. de la Monte SM, Chiche J, von dem BA, et al. Nitric oxide syn-thase-3 overexpression causes apoptosis and impairs neuronal mi-tochondrial function: relevance to Alzheimer's-type neurodegenera-tion. Lab Invest 2003; 83(2): 287-98.
138. Lahiri DK, Chen D, Ge YW, et al. Does nitric oxide synthasecontribute to the pathogenesis of Alzheimer's disease?: effects ofbeta-amyloid deposition on NOS in transgenic mouse brain withAD pathology. Ann N Y Acad Sci 2003; 1010: 639-42.
139. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van denBH. Cholinesterase inhibitors for patients with Alzheimer's disease:systematic review of randomised clinical trials. BMJ 2005;331(7512): 321-7.
140. Walker LC, Ibegbu CC, Todd CW, et al. Emerging prospects forthe disease-modifying treatment of Alzheimer's disease. BiochemPharmacol 2005; 69(7): 1001-8.
141. Sabbagh MN, Farlow MR, Relkin N, Beach TG. Do cholinergictherapies have disease-modifying effects in Alzheimer's disease? Alzheimers Dement 2006; 2(2): 118-25.
142. Thatcher GR, Bennett BM, Reynolds JN. Nitric oxide mimeticmolecules as therapeutic agents in Alzheimer's disease. Curr Alz-heimer Res 2005; 2(2): 171-82.
143. Das UN. Folic acid and polyunsaturated fatty acids improve cognitive function and prevent depression, dementia, and Alzheimer'sdisease--but how and why? Prostaglandins Leukot Essent Fatty Ac-ids 2008; 78(1): 11-19.
144. Takatori Y. [Mechanisms of neuroprotective effects of therapeuticacetylcholinesterase inhibitors used in treatment of Alzheimer'sdisease]. Yakugaku Zasshi 2006;126(8): 607-16.
145. Li W, Mak M, Jiang H, et al. Novel anti-Alzheimer's dimer Bis(7)-cognitin: cellular and molecular mechanisms of neuroprotectionthrough multiple targets. Neurotherapeutics 2009; 6(1): 187-201.
146. Maczurek A, Hager K, Kenklies M, et al. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's dis-ease. Adv Drug Deliv Rev 2008; 60(13-14): 1463-70.
147. in t, V, Ruitenberg A, Hofman A, Launer LJ, et al. Nonsteroidalantiinflammatory drugs and the risk of Alzheimer's disease. N EnglJ Med 2001; 345(21): 1515-1521.
148. Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, BreitnerJC. Reduced incidence of AD with NSAID but not H2 receptor an-tagonists: the Cache County Study. Neurology 2002; 59(6): 880-6.
149. Griffin WS, Nicoll JA, Grimaldi LM, Sheng JG, Mrak RE. Thepervasiveness of interleukin-1 in alzheimer pathogenesis: a role forspecific polymorphisms in disease risk. Exp Gerontol 2000; 35(4):481-7.
150. Wyss-Coray T, Masliah E, Mallory M, et al. Amyloidogenic role ofcytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature 1997; 389(6651): 603-6.
151. Jiang B, Du J, Liu JH, Bao YM, An LJ. Catalpol attenuates theneurotoxicity induced by beta-amyloid(1-42) in cortical neuron-gliacultures. Brain Res 2008; 1188: 139-47.
152. Chung HY, Cesari M, Anton S, et al. Molecular inflammation:underpinnings of aging and age-related diseases. Ageing Res Rev 2009; 8(1): 18-30.
153. Asanuma M, Miyazaki I, Tsuji T, Ogawa N. New aspects of neuro-protective effects of nonsteroidal anti-inflammatory drugs. NihonShinkei Seishin Yakurigaku Zasshi 2003; 23(3): 111-9.
154. Dokmeci D. Ibuprofen and Alzheimer's disease. Folia Med(Plovdiv) 2004; 46(2): 5-10.
155. Gasparini L, Ongini E, Wilcock D, Morgan D. Activity of flur-biprofen and chemically related anti-inflammatory drugs in modelsof Alzheimer's disease. Brain Res Brain Res Rev 2005; 48(2): 400-8.
156. Dheen ST, Jun Y, Yan Z, Tay SS, Ling EA. Retinoic acid inhibitsexpression of TNF-alpha and iNOS in activated rat microglia. Glia 2005; 50(1): 21-31.
157. Jana M, Jana A, Liu X, Ghosh S, Pahan K. Involvement of phos-phatidylinositol 3-kinase-mediated up-regulation of I kappa B al-pha in anti-inflammatory effect of gemfibrozil in microglia. J Im-munol 2007; 179(6): 4142-52.
158. Ayasolla K, Khan M, Singh AK, Singh I. Inflammatory mediatorand beta-amyloid (25-35)-induced ceramide generation and iNOSexpression are inhibited by vitamin E. Free Radic Biol Med 2004;37(3): 325-38.
159. Chiarugi A, Moskowitz MA. Poly(ADP-ribose) polymerase-1activity promotes NF-kappaB-driven transcription and microglialactivation: implication for neurodegenerative disorders. J Neuro-chem 2003; 85(2): 306-17.
160. Scali C, Prosperi C, Vannucchi MG, Pepeu G, Casamenti F. Braininflammatory reaction in an animal model of neuronal degenerationand its modulation by an anti-inflammatory drug: implication inAlzheimer's disease. Eur J Neurosci 2000; 12(6): 1900-12.
161. Farooqui AA, Yang HC, Horrocks L. Involvement of phospholi-pase A2 in neurodegeneration. Neurochem Int 1997; 30(6): 517-22.
162. Hicks JB, Lai Y, Sheng W, et al. Amyloid-beta peptide inducestemporal membrane biphasic changes in astrocytes through cytoso-lic phospholipase A2. Biochim Biophys Acta 2008; 1778(11):2512-9.
163. Stephenson DT, Lemere CA, Selkoe DJ, Clemens JA. Cytosolicphospholipase A2 (cPLA2) immunoreactivity is elevated in Alz-heimer's disease brain. Neurobiol Dis 1996; 3(1): 51-63.
164. Ross BM, Moszczynska A, Erlich J, Kish SJ. Phospholipid-metabolizing enzymes in Alzheimer's disease: increased lysophos-pholipid acyltransferase activity and decreased phospholipase A2activity. J Neurochem 1998; 70(2): 786-93.
165. Zhou L, Zhu DY. Neuronal nitric oxide synthase: structure, subcel-lular localization, regulation, and clinical implications. Nitric Oxide 2009; 20(4): 223-30.
166. Lockhart BP, Benicourt C, Junien JL, Privat A. Inhibitors of freeradical formation fail to attenuate direct beta-amyloid25-35 pep-tide-mediated neurotoxicity in rat hippocampal cultures. J NeurosciRes 1994; 39(4): 494-505.
167. Dvir E, Elman A, Simmons D, et al. DP-155, a lecithin derivativeof indomethacin, is a novel nonsteroidal antiinflammatory drug for analgesia and Alzheimer's disease therapy. CNS Drug Rev 2007;13(2): 260-77.
168. Chalimoniuk M, Glowacka J, Zabielna A, Eckert A, StrosznajderJB. Nitric oxide alters arachidonic acid turnover in brain cortexsynaptoneurosomes. Neurochem Int 2006; 48(1): 1-8.
169. Devan BD, Bowker JL, Duffy KB, et al. Phosphodiesterase inhibi-tion by sildenafil citrate attenuates a maze learning impairment inrats induced by nitric oxide synthase inhibition. Psychopharma-cology (Berl) 2006; 183(4): 439-45.
170. Corbin JD, Beasley A, Blount MA, Francis SH. Vardenafil: struc-tural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). Neurochem Int 2004; 45(6):859-63.
171. Mullershausen F, Russwurm M, Koesling D, Friebe A. In vivoreconstitution of the negative feedback in nitric oxide/cGMP sig-naling: role of phosphodiesterase type 5 phosphorylation. Mol BiolCell 2004; 15(9): 4023-30.
172. Puzzo D, Staniszewski A, Deng SX, et al. Phosphodiesterase 5inhibition improves synaptic function, memory, and amyloid-betaload in an Alzheimer's disease mouse model. J Neurosci 2009;29(25): 8075-86.
173. Uthayathas S, Karuppagounder SS, Thrash BM, Parameshwaran K,Suppiramaniam V, Dhanasekaran M. Versatile effects of sildenafil:recent pharmacological applications. Pharmacol Rep 2007; 59(2):150-63.
174. Domek-Lopacinska K, Strosznajder JB. Cyclic GMP metabolismand its role in brain physiology. J Physiol Pharmacol 2005; 56 Suppl 2: 15-34.
175. Kleppisch T, Wolfsgruber W, Feil S, et al. Hippocampal cGMP-dependent protein kinase I supports an age- and protein synthesis-dependent component of long-term potentiation but is not essentialfor spatial reference and contextual memory. J Neurosci 2003;23(14): 6005-12.
176. Schubert P, Morino T, Miyazaki H, et al. Cascading glia reactions:a common pathomechanism and its differentiated control by cyclicnucleotide signaling. Ann N Y Acad Sci 2000; 903: 24-33.
177. Frampton M, Harvey RJ, Kirchner V. Propentofylline for dementia. Cochrane Database Syst Rev 2003; (2): CD002853.
178. Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E.Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitatesthe establishment of long-lasting long-term potentiation and im-proves memory. Proc Natl Acad Sci USA 1998; 95(25): 15020-5.
179. Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O.Persistent improvement in synaptic and cognitive functions in anAlzheimer mouse model after rolipram treatment. J Clin Invest 2004; 114(11): 1624-34.
180. Arendash GW, Schleif W, Rezai-Zadeh K, et al. Caffeine protectsAlzheimer's mice against cognitive impairment and reduces brainbeta-amyloid production. Neuroscience 2006; 142(4): 941-52.
181. Dall'Igna OP, Fett P, Gomes MW, Souza DO, Cunha RA, Lara DR.Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp Neurol 2007; 203(1): 241-5.
182. Poucher SM, Keddie JR, Singh P, et al. The in vitro pharmacologyof ZM 241385, a potent, non-xanthine A2a selective adenosine re-ceptor antagonist. Br J Pharmacol 1995; 115(6): 1096-102.
183. Baratti CM, Boccia MM, Blake MG. Pharmacological effects andbehavioral interventions on memory consolidation and reconsolida-tion. Braz J Med Biol Res 2009; 42(2): 148-54.
184. Southan GJ, Szabo C. Selective pharmacological inhibition ofdistinct nitric oxide synthase isoforms. Biochem Pharmacol 1996;51(4): 383-94.
185. de la Torre JC, Aliev G. Inhibition of vascular nitric oxide after ratchronic brain hypoperfusion: spatial memory and immunocyto-chemical changes. J Cereb Blood Flow Metab 2005; 25(6): 663-72.
186. Wilcock DM, Lewis MR, Van Nostrand WE, et al. Progression ofamyloid pathology to Alzheimer's disease pathology in an amyloidprecursor protein transgenic mouse model by removal of nitric ox-ide synthase 2. J Neurosci 2008; 28(7): 1537-45.
187. Colton CA, Vitek MP, Wink DA, et al. NO synthase 2 (NOS2)deletion promotes multiple pathologies in a mouse model of Alz-heimer's disease. Proc Natl Acad Sci USA 2006; 103(34): 12867-72.
188. Salerno L, Sorrenti V, Di GC, Romeo G, Siracusa MA. Progress inthe development of selective nitric oxide synthase (NOS) inhibi-tors. Curr Pharm Des 2002; 8(3): 177-200
189. Moore PK, al-Swayeh OA, Chong NW, Evans RA, Gibson A. L-NG-nitro arginine (L-NOARG), a novel, L-arginine-reversible in-hibitor of endothelium-dependent vasodilatation in vitro. Br JPharmacol 1990; 99(2): 408-12.
190. Babu BR, Griffith OW. N5-(1-Imino-3-butenyl)-L-ornithine. Aneuronal isoform selective mechanism-based inactivator of nitricoxide synthase. J Biol Chem 1998; 273(15): 8882-9.
191. Furfine ES, Harmon MF, Paith JE, Garvey EP. Selective inhibitionof constitutive nitric oxide synthase by L-NG-nitroarginine. Bio-chemistry 1993; 32(33): 8512-7.
192. Narayanan K, Griffith OW. Synthesis of L-thiocitrulline, L-homothiocitrulline, and S-methyl-L-thiocitrulline: a new class ofpotent nitric oxide synthase inhibitors. J Med Chem 1994; 37(7):885-7.
193. Narayanan K, Spack L, McMillan K, et al. S-alkyl-L-thiocitrullines. Potent stereoselective inhibitors of nitric oxide syn-thase with strong pressor activity in vivo. J Biol Chem 1995;270(19): 11103-10.
194. Furfine ES, Harmon MF, Paith JE, et al. Potent and selectiveinhibition of human nitric oxide synthases. Selective inhibition ofneuronal nitric oxide synthase by S-methyl-L-thiocitrulline and S-ethyl-L-thiocitrulline. J Biol Chem 1994; 269(43): 26677-83.
195. Ulhaq S, Chinje EC, Naylor MA, Jaffar M, Stratford IJ, ThreadgillMD. Heterocyclic analogues of L-citrulline as inhibitors of the iso-forms of nitric oxide synthase (NOS) and identification of N(delta)-(4,5-dihydrothiazol-2-yl)ornithine as a potent inhibitor. BioorgMed Chem 1999; 7(9): 1787-96.
196. Eustache J, Grob A, Lam C, Sellier O, Schulz G. Conformationallyconstrained NO synthase inhibitors: rigid analogs of L-N-iminoethylornithine. Bioorg Med Chem Lett 1998; 8(21): 2961-6.
197. Huang H, Martasek P, Roman LJ, Masters BS, Silverman RB.N(omega)-Nitroarginine-containing dipeptide amides. Potent andhighly selective inhibitors of neuronal nitric oxide synthase. J MedChem 1999; 42(16): 3147-53.
198. Kobayashi N, Higuchi T, Urano Y, Kikuchi K, Hirobe M, NaganoT. Dipeptides containing L-arginine analogs: new isozyme-selective inhibitors of nitric oxide synthase. Biol Pharm Bull 1999;22(9): 936-40.
199. Sohn MJ, Hur GM, Byun HS, Kim WG. Cyclo(dehydrohistidyl-l-tryptophyl) inhibits nitric oxide production by preventing the di-merization of inducible nitric oxide synthase. Biochem Pharmacol 2008; 75(4): 923-30.
200. Cross AH, Misko TP, Lin RF, Hickey WF, Trotter JL, Tilton RG.Aminoguanidine, an inhibitor of inducible nitric oxide synthase,ameliorates experimental autoimmune encephalomyelitis in SJLmice. J Clin Invest 1994; 93(6): 2684-90.
201. Garvey EP, Oplinger JA, Tanoury GJ, et al. Potent and selectiveinhibition of human nitric oxide synthases. Inhibition by non-aminoacid isothioureas. J Biol Chem 1994; 269(43): 26669-76.
202. Moore WM, Webber RK, Fok KF, et al. 2-Iminopiperidine andother 2-iminoazaheterocycles as potent inhibitors of human nitricoxide synthase isoforms. J Med Chem 1996; 39(3): 669-72.
203. Naka M, Nanbu T, Kobayashi K, et al. A potent inhibitor of induc-ible nitric oxide synthase, ONO-1714, a cyclic amidine derivative.Biochem Biophys Res Commun 2000; 270(2): 663-7.
204. Babbedge RC, Bland-Ward PA, Hart SL, Moore PK. Inhibition ofrat cerebellar nitric oxide synthase by 7-nitro indazole and relatedsubstituted indazoles. Br J Pharmacol 1993; 110(1): 225-8.
205. Yoshida T, Limmroth V, Irikura K, Moskowitz MA. The NOSinhibitor, 7-nitroindazole, decreases focal infarct volume but notthe response to topical acetylcholine in pial vessels. J Cereb BloodFlow Metab 1994; 14(6): 924-9.
206. Schulz JB, Beal MF. Neuroprotective effects of free radical scav-engers and energy repletion in animal models of neurodegenerativedisease. Ann N Y Acad Sci 1995; 765: 100-10.
207. White KA, Marletta MA. Nitric oxide synthase is a cytochrome P-450 type hemoprotein. Biochemistry 1992; 31(29): 6627-31.
208. Wolff DJ, Datto GA, Samatovicz RA, Tempsick RA. Calmodulin-dependent nitric-oxide synthase. Mechanism of inhibition by imi-dazole and phenylimidazoles. J Biol Chem 1993; 268(13): 9425-9.
209. Rogerson TD, Wilkinson CF, Hetarski K. Steric factors in theinhibitory interaction of imidazoles with microsomal enzymes. Biochem Pharmacol 1977; 26(11): 1039-42.
210. Mayer B, Werner ER. In search of a function for tetrahydrobiop-terin in the biosynthesis of nitric oxide. Naunyn SchmiedebergsArch Pharmacol 1995; 351(5): 453-63.
211. Bommel HM, Reif A, Frohlich LG, et al. Anti-pterins as tools tocharacterize the function of tetrahydrobiopterin in NO synthase. JBiol Chem 1998; 273(50): 33142-9.
212. Terpolilli NA, Zweckberger K, Trabold R, et al. The novel nitricoxide synthase inhibitor 4-amino-tetrahydro-L-biopterine preventsbrain edema formation and intracranial hypertension followingtraumatic brain injury in mice. J Neurotrauma 2009; 26(11): 1963-75.
213. Monsonego A, Weiner HL. Immunotherapeutic approaches toAlzheimer's disease. Science 2003; 302(5646): 834-8.
214. Gelinas DS, DaSilva K, Fenili D, St George-Hyslop P, McLaurin J.Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci USA 2004; 101 Suppl 2: 14657-62.
215. Weiner HL, Frenkel D. Immunology and immunotherapy of Alz-heimer's disease. Nat Rev Immunol 2006; 6(5): 404-16.Received: July 9, 2010 Accepted: July 21, 2010
216. Kellner A, Matschke J, Bernreuther C, Moch H, Ferrer I, GlatzelM. Autoantibodies against beta-amyloid are common in Alz-heimer's disease and help control plaque burden. Ann Neurol 2009;65(1): 24-31.
217. Klyubin I, Walsh DM, Lemere CA, et al. Amyloid beta proteinimmunotherapy neutralizes Abeta oligomers that disrupt synapticplasticity in vivo. Nat Med 2005; 11(5): 556-61.
218. Weldon DT, Rogers SD, Ghilardi JR, et al. Fibrillar beta-amyloidinduces microglial phagocytosis, expression of inducible nitric ox-ide synthase, and loss of a select population of neurons in the ratCNS in vivo. J Neurosci 1998; 18(6): 2161-73.
219. Cho DH, Nakamura T, Fang J, et al. S-nitrosylation of Drp1 medi-ates beta-amyloid-related mitochondrial fission and neuronal in-jury. Science 2009; 324(5923): 102-5.